Understanding and utilising mutations
to improve the effectiveness of
treatments and vaccines
Scroll
In both oncology and virology, the rapid progression of diseases, biological variability and the emergence of resistance are making therapeutic decisions increasingly uncertain. These challenges expose those involved in drug development to repeated clinical failures and highlight a critical need:
To gain a detailed understanding of the actual impact of mutations on biology
Born from over twenty years of academic research in computational biology, Lafame is a deeptech company, a CNRS spin-off, that develops digital health solutions to analyze the physiopathological consequences of mutations and help drug industry stakeholders make better therapeutic decisions. Unlike purely predictive approaches, Lafame relies on deterministic models and sovereign infrastructures, prioritizing understanding, explainability, and data control to deliver reliable and actionable results.
This approach is now embodied in two complementary software solutions, one dedicated to virology, the other to oncology.
In virology, AfterVir analyses the effect of viral mutations on therapeutic targets, identifies resistance and helps to optimise vaccine formulation. It is backed by robust evidence, including a proof-of-concept study conducted with the Pasteur Institute on the influenza virus (H1N1), and supports Lafame's most advanced offering dedicated to the genetic optimisation of antiviral vaccines.
In oncology, OncoTwin is a universal digital twin that analyses the impact of mutations on a large scale. It enables the stratification of patient populations to improve the design of phase 2 and 3 clinical trials, whilst also identifying opportunities for therapeutic repositioning and repurposing.
At the heart of Lafame lies a multidisciplinary team, bringing together computational biology, mathematics, data science, oncology, virology and pharmaceutical business expertise. This diversity is essential for bridging the gap between biological complexity and industrial and clinical realities.
At the intersection of biology, digital technology and industrial challenges, Lafame designs solutions aimed at reducing uncertainty and improving the effectiveness of treatments, for the benefit of both the pharmaceutical industry and patients.